TB-500 Dosage Guide

TB-500 is a synthetic version of the active region of Thymosin Beta-4 (Tβ4), a protein present in virtually all human and animal cells. Thymosin Beta-4 plays a central role in cell migration, blood vessel formation, and tissue repair processes.

In animal studies, TB-500 has demonstrated significant effects on wound healing, inflammation reduction, and cardiac tissue repair following ischemic injury. Its mechanism of action involves upregulation of actin, a cell-building protein critical for cell migration and proliferation. TB-500 is used exclusively for research purposes.

TB-500 protocols typically involve a loading phase followed by a maintenance phase. The following table outlines common research dosages:

The loading phase saturates tissues with the peptide, while the maintenance phase sustains elevated levels. Most researchers begin with 2 mg per injection, administered 2–3 times weekly during loading.

TB-500 has a relatively long half-life compared to many peptides, allowing for less frequent dosing. During the loading phase, injections are typically spaced evenly throughout the week (e.g., Monday/Thursday or Monday/Wednesday/Friday).

Cycling: A standard cycle consists of 4–6 weeks loading followed by 4–8 weeks maintenance. After completing a full cycle (8–14 weeks total), a break of 4–6 weeks is commonly observed before initiating a new cycle.

TB-500 is provided as a lyophilized powder requiring reconstitution with bacteriostatic water.

• Step 1: Swab both vial stoppers with alcohol.
• Step 2: For a 5 mg vial, add 1 mL of BAC water to yield 5 mg/mL (each 0.1 mL = 500 mcg).
• Step 3: Direct the BAC water stream along the glass wall. Allow the powder to dissolve naturally.
• Step 4: Gently swirl — do not shake or vortex aggressively.
• Step 5: Refrigerate at 2–8°C. Use within 21 days of reconstitution.

Administer subcutaneously using a 29–31 gauge insulin syringe. TB-500 is systemically active, so injection site is less critical than with localized peptides like BPC-157.

TB-500 is generally well-tolerated in animal studies. Reported side effects in anecdotal research logs include:

• Standard doses (4–5 mg/week): Mild injection site irritation, temporary lethargy, slight head rush post-injection.
• Higher doses (7.5+ mg/week): Increased frequency of headache, possible flu-like symptoms during loading phase, temporary hair growth changes noted in some animal models.

No serious adverse events have been documented in published animal studies at standard research doses.

TB-500 is for research purposes only and is not approved for human use by any regulatory agency.

Due to its role in promoting cell migration and angiogenesis, TB-500 should not be used in subjects with active malignancies. Consult a qualified healthcare professional before initiating any research protocol. Store all peptides properly and use sterile technique for all injections.